+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
LINCOLN

Lincoln Pharmaceuticals Share Price

₹623.50 -10.9 (-1.72%)
41.70% Gain from 52W Low

11 Sep, 2026 3:58 PM (IST)

Lincoln Pharmaceuticals live price: ₹623.50. It opened at ₹635 vs previous close ₹634; intraday high/low: ₹635/₹619. The 50 & 200 DMA stand at ₹615.10/₹598.20.

Lincoln Pharmaceuticals Performance

  • Today's Low
  • ₹619
  • Today's High
  • ₹635
  • 52 Week Low
  • ₹440
  • 52 Week High
  • ₹770
  • Open Price₹635
  • Previous Close₹634
  • Volume42,109
  • 50 DMA₹615.10
  • 100 DMA₹610.70
  • 200 DMA₹598.20

Lincoln Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 4.53%
  • Over 3 Month -0.98%
  • Over 6 Month + 0.27%
  • Over 1 Year + 11.6%

Smart Investing Starts Here Start SIP with Lincoln Pharmaceuticals for Steady Growth!

Invest Now

Lincoln Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.9
  • PEG Ratio
  • 1.1
  • Market Cap Cr
  • 1,249
  • P/B Ratio
  • 1.6
  • Average True Range
  • 16.8
  • EPS
  • 48.2
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 6.9
  • RSI
  • 53.37
  • MFI
  • 64.65

Latest Stock News Updates

Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication for Notice of 32nd Annual General Meeting.

Lincoln Pharmaceuticals Ltd - 531633 - Update Regarding Dispatch Of Physical Communication To Shareholders To Access Annual Report Of The Company.

Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address.

Lincoln Pharmaceuticals Ltd - 531633 - Reg. 34 (1) Annual Report.

Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the SEBI Listing Regulations"), we are submitting herewith the Annual Report of the Company along with the Notice of 32nd Annual General Meeting ("AGM") for the Financial Year 2025-2026.

Lincoln Pharmaceuticals Financials

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹623.50
-10.9 (-1.72%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹620.40
  • 50 Day
  • ₹615.10
  • 100 Day
  • ₹610.70
  • 200 Day
  • ₹598.20

Resistance and Support

625.87 Pivot Speed
  • R3 648.50
  • R2 641.80
  • R1 632.60
  • S1 616.70
  • S2 610.00
  • S3 600.80

Lincoln Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-13 Quarterly Results
2026-05-28 Audited Results & Final Dividend
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-07 Quarterly Results
Date Purpose Remarks
2026-09-11 FINAL Rs.1.80 per share(18%)Final Dividend
2025-09-12 FINAL Rs.1.80 per share(18%)Final Dividend
View Lincoln Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2009-03-26 Split Consolidation of shares from Rs. 2/- to Rs. 10/-.
2006-02-16 Split Stock split from Rs. 10/- to Rs. 2/-

Lincoln Pharmaceuticals Shareholding Pattern

49.78%
45.36%
4.6%
0.27%

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products. View More
  • NSE Symbol
  • LINCOLN
  • BSE Symbol
  • 531633
  • ISIN
  • INE405C01035

Similar Stocks to Lincoln Pharmaceuticals

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹623 As on 12 September, 2026 | 16:37

The Market Cap of Lincoln Pharmaceuticals is ₹1248.9 Cr As on 12 September, 2026 | 16:37

The P/E ratio of Lincoln Pharmaceuticals is 12.9 As on 12 September, 2026 | 16:37

The PB ratio of Lincoln Pharmaceuticals is 1.6 As on 12 September, 2026 | 16:37

The 52 week High & Low of Lincoln Pharmaceuticals is ₹770/₹440 respectively As on 12 September, 2026 | 16:37

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23